+1,058.4%
ASML vs MRNA
+561.6%
+496.8%
-56.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.2% | -2.2% | +6.4% | +4.3% |
| 7D | +1.1% | +5.5% | -4.4% | +0.7% |
| 30D | +2.2% | +158.7% | -156.5% | -10.3% |
| 3M | -2.3% | +182.1% | -184.4% | -15.7% |
| 6M | +23.0% | +151.8% | -128.8% | +7.3% |
| YTD | +61.1% | +393.6% | -332.5% | +28.8% |
| 1Y | +129.1% | +499.5% | -370.4% | +77.7% |
| 3Y | +165.4% | +29.3% | +136.0% | +136.1% |
| 5Y | +109.5% | -65.1% | +174.5% | +98.3% |
| All | +1,058.4% | +561.6% | +496.8% | +904.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling